Exploring new drug combinations for advanced prostate cancer treatment
Synthetic lethal metabolic drug combinations for castration-resistant prostate cancer
['FUNDING_CAREER'] · JOHNS HOPKINS UNIVERSITY · NIH-10846603
This study is looking at a new treatment called Bipolar Androgen Therapy (BAT) for men with castration-resistant prostate cancer, aiming to find ways to make this therapy work better by targeting how hormones affect cancer metabolism, so participants might get access to cutting-edge options that aren't widely available yet.
Quick facts
| Phase | ['FUNDING_CAREER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | JOHNS HOPKINS UNIVERSITY (nih funded) |
| Locations | 1 site (BALTIMORE, UNITED STATES) |
| Trial ID | NIH-10846603 on ClinicalTrials.gov |
What this research studies
This research investigates how certain metabolic programs influenced by hormones can be targeted to treat castration-resistant prostate cancer. The approach involves using a novel therapy called Bipolar Androgen Therapy (BAT), which administers high doses of androgens intermittently to prevent the cancer from adapting and becoming resistant. The study aims to identify specific metabolic vulnerabilities that can be exploited to enhance the effectiveness of this therapy. Patients participating in this research may have the opportunity to receive innovative treatment options that are currently not widely available.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with castration-resistant prostate cancer who have not responded well to standard therapies.
Not a fit: Patients with early-stage prostate cancer or those who have not yet undergone androgen deprivation therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide new therapeutic options for patients with advanced prostate cancer who have limited treatment choices.
How similar studies have performed: Previous research has shown promising results with similar approaches, particularly in the use of Bipolar Androgen Therapy for prostate cancer.
Where this research is happening
BALTIMORE, UNITED STATES
- JOHNS HOPKINS UNIVERSITY — BALTIMORE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SENA, LAURA A. — JOHNS HOPKINS UNIVERSITY
- Study coordinator: SENA, LAURA A.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancer Treatment